

## **MEDIA STATEMENT**

PHILOGEN SPA ANNOUNCES PARTICIPATION TO THE “CHI IMMUNO-ONCOLOGY SUMMIT EUROPE”, MARCH 20-24, 2017, LONDON, UK

[Philogen S.p.A.](#) and its fully owned subsidiary [Philochem AG](#), announce their participation to the “[CHI Immuno-Oncology Summit Europe](#)” that will take place at the Hilton Canary Wharf in London on March 20-24, 2017.

The full week conference, organized by the Cambridge Innovation Institute, will cover three main areas: Novel Approaches for Cancer, Immunomodulatory Approaches and Combination Immunotherapy.

**Prof. Dr. Dario Neri**, Swiss Federal Institute of Technology Zurich, co-founder and Chairman of the scientific advisory board of Philogen, will give a talk with the title “[Investigations into Mechanisms of Immune Tumour Rejection](#)”. The presentation is scheduled for Wednesday, March 22 in the “*Current Understanding Of The Role Of The Immune System In Cancer*” section.

For additional news and press release topics, visit: <http://www.philogen.com/en/news/>

### **About the Philogen group**

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit [www.philogen.com](http://www.philogen.com)

---